Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients

Klaff, Rami; Varenhorst, Eberhard; Berglund, Anders; Hedlund, Per Olov; Sjöberg, Folke; Sandblom, Gabriel

doi:10.1080/21681805.2016.1209689

Cited by 7 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study was based on the Scandinavian Prostate Cancer Group (SPCG) Trial number 5, a Phase III study in which 915 men with hormone‐naive M1b prostate cancer were included from 61 centres in Denmark, Finland, Iceland, Norway and Sweden between December 1992 and June 1997 . The SPCG‐5 was designed as a non‐inferiority trial.…”

Section: Methodsmentioning

confidence: 99%

“…Inclusion criteria were skeletal metastases (M1b) and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–2, where: 0 = fully active; 1 = restriction in strenuous activity but ambulatory; and 2 = ambulatory and capable of self‐care but unable to work. The primary objective of the trial was to determine whether survival after high‐dose parenteral oestrogen therapy was not inferior to that after total androgen blockade (TAB) . The secondary objective was to provide information on cardiovascular side‐effects and health‐related quality of life (QoL) before and during ADT .…”

Section: Methodsmentioning

confidence: 99%

“…The extent of the primary tumour was determined using DRE according to the TNM classification from 1987 and cytological or histological specimens graded according to the WHO system. PSA, alkaline phosphatase (ALP), testosterone and Hb levels were determined by routine laboratory testing before the start of treatment . Skeletal involvement was assessed using bone scans supplemented by X‐ray in selected cases .…”

Section: Methodsmentioning

confidence: 99%

“…PSA, alkaline phosphatase (ALP), testosterone and Hb levels were determined by routine laboratory testing before the start of treatment . Skeletal involvement was assessed using bone scans supplemented by X‐ray in selected cases . The extent of bone metastases was quantified according to a modified three‐grade Soloway Score where: 1 = the total area of hot spots <3 lumbar vertebral bodies; 2 = the total area of hot spots larger than Score 1, but <75% of the total scan; and 3 = ≥75% of the total scan or super scan.…”

Section: Methodsmentioning

confidence: 99%

“…The extent of bone metastases was quantified according to a modified three‐grade Soloway Score where: 1 = the total area of hot spots <3 lumbar vertebral bodies; 2 = the total area of hot spots larger than Score 1, but <75% of the total scan; and 3 = ≥75% of the total scan or super scan. QoL was rated by The European Organisation of Research and Treatment of Cancer Quality‐of‐Life Questionnaire 30‐item core (C30) .…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen‐deprivation therapy for hormone‐naïve bone‐metastatic prostate cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

In a large cohort of Scandinavian men with hormone-naïve M1b prostate cancer, an increase in Hb concentration between baseline and 3 months of ADT was associated with significantly poorer survival, whereas an increase between 6 and 12 months was associated with better survival. These findings provide new information about patterns of change in Hb concentrations during 12 months of ADT for M1b prostate cancer, and survival. Clinicians should be aware of the prognostic value of Hb concentration changes during ADT in M1b prostate cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen‐deprivation therapy for hormone‐naïve bone‐metastatic prostate cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

Purpose To assess the prognostic value of alkaline phosphatase in patients with hormone-sensitive prostate cancer. Methods A systematic review and meta-analysis was performed using the PUBMED, Web of Science, Cochrane Library, and Scopus in April 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared hormone-sensitive prostate cancer patients with high vs. low alkaline phosphatase to determine its predictive value for overall survival, cancer-specific survival, and progression-free survival. We performed a formal meta-analysis of these outcomes. Results 42 articles with 7938 patients were included in the systematic review and 28 studies with 5849 patients for the qualitative assessment. High alkaline phosphatase was associated with worse overall survival (pooled HR 1.72; 95% CI 1.37−2.14) and progression-free survival (pooled HR 1.30; 95% CI 1.10−1.54). In subgroup analyses of patients with "high-volume" and "low-volume", alkaline phosphatase was associated with the overall survival (pooled HR 1.41; 95% CI 1.21−1.64 and pooled HR 1.64; 95% CI, 1.06−2.52, respectively). Conclusions In this meta-analysis, elevated serum levels of alkaline phosphatase were associated with an increased risk of overall mortality and disease progression in patients with hormone-sensitive prostate cancer. In contrast, those were not associated with an increased risk of cancer-specific mortality. Alkaline phosphatase was independently associated with overall survival in both patients with "high-volume" and "low-volume" hormone-sensitive prostate cancer. Alkaline phosphatase may be useful for being integrated into prognostic tools that help guide treatment strategy, thereby facilitating the shared decision making process.

show abstract

Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients

Cited by 7 publications

References 27 publications

Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen‐deprivation therapy for hormone‐naïve bone‐metastatic prostate cancer

Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen‐deprivation therapy for hormone‐naïve bone‐metastatic prostate cancer

Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer

Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About